Hemophilus influenzae type b (Hib) is a bacterium that can cause a number of serious diseases, especially among young children, like pneumonia and meningitis that account for nearly 20% of deaths globally. The global research and development organization Hilleman Laboratories has conducted the pre-clinical trial for a new Hib vaccine, which can offer affordable treatment to children having viral diseases, revealed a top company official.
The unique formulation derived from the ongoing research will not only bring down the cost of the Hib vaccine, but will also provide a scalable platform for commercial manufacturing.
Davinder Gill, CEO, Hilleman Laboratories, said, "Capsular polysaccharide conjugates of Hib are important components of several mono-or multivalent vaccines for children. However, the access to needy people is limited due to the relative high cost of the Hib vaccine. This new formulation will be a step towards developing a cost-effective and a more immunogenic vaccine. It is an encouraging breakthrough in bridging the gap and making Hib vaccine accessible and affordable."
Gill further added, "A strategic three-step approach was used to identify the efficacy of polysaccharide in preparing a vaccine for Hib. We have already completed the preclinical immunogenicity trial phase which has shown predictive results. Our next step now would be to look at collaboration with like-minded stakeholders who can work together towards cost effective solutions with the aim of bridging existing gaps in a significant way."
The report of this successful trial has been published in Vaccine.